|3 -0.27 (-8.26%)||12-01 15:59|
|Targets||6-month :||5.24||1-year :||6.12|
|Resists||First :||4.48||Second :||5.24|
|Supports||First :||1.83||Second :||0.2|
|MAs||MA(5) :||2.13||MA(20) :||0.74|
|MA(100) :||0.45||MA(250) :||0.79|
|MACD||MACD :||0.5||Signal :||0.2|
|%K %D||K(14,3) :||74.4||D(3) :||58.3|
|52-week||High :||4.48||Low :||0.2|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IBIO ] has closed below upper band by 8.3%. Bollinger Bands are 1855.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||3.14 - 3.16||3.16 - 3.17|
|Low:||2.76 - 2.78||2.78 - 2.8|
|Close:||2.97 - 3||3 - 3.03|
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Fri, 01 Dec 2023
Is Ibio Inc (IBIO) Stock Worth a Buy Friday? - InvestorsObserver
Mon, 27 Nov 2023
iBio Announces Reverse Stock Split - Yahoo Finance
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||0 (M)|
|Held by Insiders||0 (%)|
|Held by Institutions||0 (%)|
|Shares Short||0 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||0 %|
|Return on Equity (ttm)||0 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||0 (M)|
|Price to Book value||0|
|Price to Sales||0|
|Price to Cash Flow||0|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|